Literature DB >> 18644631

The Lambert-Eaton myasthenic syndrome 1988-2008: a clinical picture in 97 patients.

M J Titulaer1, P W Wirtz, J B M Kuks, H J Schelhaas, A J van der Kooi, C G Faber, W L van der Pol, M de Visser, P A E Sillevis Smitt, J J G M Verschuuren.   

Abstract

BACKGROUND: Neuromuscular symptoms in patients with Lambert-Eaton myasthenic syndrome (LEMS) and a small cell lung cancer (SCLC) develop more rapidly than in LEMS patients without a SCLC. We studied how this clinical information, which is readily available at the first consultation, can be used to predict the presence of SCLC. PATIENTS AND METHODS: In our study we included 52 LEMS patients with SCLC and 45 non-tumor patients (NT-LEMS). We interviewed patients using a structured checklist and reviewed their clinical records. We compared frequency and onset of symptoms during the course of LEMS.
RESULTS: In the first six months, over half the SCLC-LEMS patients had developed seven separate symptoms, while NT-LEMS patients developed only two symptoms. Proximal leg weakness and dry mouth were early symptoms in both groups. Rapid involvement of proximal arm muscles (p=0.0001), distal arm muscles (p=0.0037), distal leg muscles (p=0.0002), dysartria (p=0.0091) and the presence of erectile dysfunction (p=0.007) were found significantly more often in SCLC-LEMS patients in both cohorts. Cerebellar symptoms, although present in 9% of LEMS patients, were almost exclusively related to SCLC-LEMS.
CONCLUSION: A rapidly progressive course of disease from onset in LEMS patients should raise a high suspicion of SCLC. Special attention should be paid to involvement of upper extremities, involvement of distal arm and distal leg muscles, to erectile dysfunction and probably ataxia in order to discriminate between SCLC-LEMS and NT-LEMS.

Entities:  

Mesh:

Year:  2008        PMID: 18644631     DOI: 10.1016/j.jneuroim.2008.05.025

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  26 in total

1.  Lambert-Eaton Myasthenic Syndrome with A Twenty-Three-Year Delay in Diagnosis.

Authors:  Elif Gökçal; Azize Esra Gürsoy; Talip Asil; Mustafa Ertaş
Journal:  Noro Psikiyatr Ars       Date:  2017-01-19       Impact factor: 1.339

Review 2.  Paraneoplastic syndromes associated with lung cancer.

Authors:  Nobuhiro Kanaji; Naoki Watanabe; Nobuyuki Kita; Shuji Bandoh; Akira Tadokoro; Tomoya Ishii; Hiroaki Dobashi; Takuya Matsunaga
Journal:  World J Clin Oncol       Date:  2014-08-10

3.  Update on paraneoplastic neurologic disorders.

Authors:  Josep Dalmau; Myrna R Rosenfeld
Journal:  Community Oncol       Date:  2010-05-01

Review 4.  Voltage gated calcium channel antibody-related neurological diseases.

Authors:  Can Ebru Bekircan-Kurt; Eda Derle Çiftçi; Aslı Tuncer Kurne; Banu Anlar
Journal:  World J Clin Cases       Date:  2015-03-16       Impact factor: 1.337

Review 5.  Italian recommendations for Lambert-Eaton myasthenic syndrome (LEMS) management.

Authors:  A Evoli; R Liguori; A Romani; R Mantegazza; A Di Muzio; B Giometto; E Pegoraro; C Rodolico; M C Vigliani
Journal:  Neurol Sci       Date:  2014-01-31       Impact factor: 3.307

6.  Screening for tumours in paraneoplastic syndromes: report of an EFNS task force.

Authors:  M J Titulaer; R Soffietti; J Dalmau; N E Gilhus; B Giometto; F Graus; W Grisold; J Honnorat; P A E Sillevis Smitt; R Tanasescu; C A Vedeler; R Voltz; J J G M Verschuuren
Journal:  Eur J Neurol       Date:  2010-09-29       Impact factor: 6.089

Review 7.  The role of laminins in the organization and function of neuromuscular junctions.

Authors:  Robert S Rogers; Hiroshi Nishimune
Journal:  Matrix Biol       Date:  2016-09-07       Impact factor: 11.583

Review 8.  Management of small-cell lung cancer: incremental changes but hope for the future.

Authors:  Christine L Hann; Charles M Rudin
Journal:  Oncology (Williston Park)       Date:  2008-11-30       Impact factor: 2.990

Review 9.  Physiologic alterations in ataxia: channeling changes into novel therapies.

Authors:  Vikram G Shakkottai; Henry L Paulson
Journal:  Arch Neurol       Date:  2009-10

10.  Complete reversal of Lambert-Eaton myasthenic syndrome synaptic impairment by the combined use of a K+ channel blocker and a Ca2+ channel agonist.

Authors:  Tyler B Tarr; David Lacomis; Stephen W Reddel; Mary Liang; Guillermo Valdomir; Michael Frasso; Peter Wipf; Stephen D Meriney
Journal:  J Physiol       Date:  2014-07-11       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.